About BioRestorative Therapies
BioRestorative Therapies (NASDAQ:BRTX) focuses on developing products and therapies using cell and tissue protocols, primarily aimed at addressing unmet medical needs. Their operations cover a broad spectrum of developmental projects, such as innovative treatments for metabolic disorders and disc/spine disease management through their ThermoStem® and brtxDISC™ programs. BioRestorative Therapies’ objective is to pioneer in the sphere of regenerative medicine by advancing these programs to commercial stages, thereby offering new therapeutic options to patients and the broader healthcare community. With a commitment to scientific excellence and innovation, the company seeks to improve the quality of life for individuals suffering from conditions that currently have limited treatment options.
Snapshot
Operations
Products and/or services of BioRestorative Therapies
- ThermoStem is a program using brown adipose tissue-derived stem cells to potentially treat metabolic disorders including diabetes and obesity.
- BRTX-100 is a product developed for treating chronic lumbar disc disease using a patient's own stem cells.
- A hair restoration project focuses on developing methods to regenerate hair using stem cell technology.
- Research in developing biological solutions to repair disc spine without the need for surgical intervention.
- Engagement in developing therapies for osteoarthritis and other musculoskeletal diseases based on stem cell and tissue engineering techniques.
BioRestorative Therapies executive team
- Mr. Lance AlstodtChairman of the Board, President & CEO
- Mr. Robert Eugene KristalChief Financial Officer
- Mr. Francisco J. SilvaVP of Research & Development, Secretary and Director
- Stephen KilmerInvestor Relations Officer
- Ms. Crystal RomanoHead of Global Commercial Operations